Table 2.
Intervention characteristics of the included studies.
| Author and Year | CP (n) | Control (n) | Male % | Age (μ ± σ) |
Time from Symptom Onset to Intervention (μ ± σ) |
CP Dose (mL) |
|---|---|---|---|---|---|---|
| Abani (2021) | 5795 | 5763 | 64% | 63.50 ± 14.70 | 9.00 ± 4.45 | 550 |
| Agarwal (2020) | 235 | 229 | 76% | 51.13 ± 19.53 | 8.35 ± 3.73 | 400 |
| Alemany (2022) | 188 | 188 | 54% | 56.70 ± 7.44 | 4.40 ± 1.40 | 275 |
| AlQahtani (2021) | 20 | 20 | 80% | 51.65 ± 19.45 | 10.00 | 400 |
| Avendaño-Solá (2021) | 179 | 171 | 65% | 63.00 ± 15.30 | 5.65 ± 2.23 | 275 |
| Bajpai (2020) | 14 | 15 | 73% | 48.20 ± 9.80 | 3.00 | 500 |
| Bajpai (2022) | 200 | 200 | 67% | 55.52 ± 1.17 | - | 500 |
| Baldeón (2022) | 63 | 95 | 68% | 74.34 ± 18.39 | 10.60 ± 4.90 | - |
| Bar (2021) | 40 | 39 | 46% | - | 7.71 ± 4.53 | - |
| Bégin (2021) | 625 | 313 | 59% | 67.50 ± 15.60 | 7.90 ± 3.70 | 500 |
| Bennett-Guerrero (2021) | 59 | 15 | 60% | 65.70 ± 23.50 | 11.12 ± 9.12 | 480 |
| Denkinger (2022) | 68 | 66 | 68% | 68.50 ± 11.30 | 7.00 ± 4.50 | 575 |
| Devos (2022) | 320 | 163 | 69% | 62.00 ± 14.00 | 7.00 ± 4.46 | 450 |
| Estcourt (2021) | 1078 | 909 | 68% | 60.77 ± 18.38 | - | 550 |
| Gharbharan (2021) | 43 | 43 | 72% | 64.40 ± 13.45 | 10.35 ± 6.72 | 300 |
| Gharbharan (2022) | 207 | 209 | 78% | 60.00 ± 7.44 | 5.00 ± 1.49 | 400 |
| Holm (2021) | 17 | 14 | 61% | 69.95 ± 40.64 | 7.00 ± 3.23 | 675 |
| Kirenga (2021) | 69 | 67 | 71% | 50.18 ± 17.61 | 6.30 ± 3.00 | - |
| Korley (2021) | 257 | 254 | 46% | 51.90 ± 16.35 | 3.65 ± 2.24 | 250 |
| Li (2020) | 52 | 51 | 58% | 70.00 ± 12.03 | 29.65 ± 14.29 | - |
| Libster (2021) | 80 | 80 | 38% | 77.20 ± 8.60 | 1.65 ± 0.58 | 250 |
| Manzini (2022) | 60 | 60 | 72% | 65.48 ± 11.96 | 8.35 ± 5.23 | 600 |
| Menichetti (2021) | 232 | 241 | 64% | 64.00 ± 14.87 | 7.21 ± 2.98 | 400 |
| O’Donnell (2021) | 150 | 73 | 66% | 60.30 ± 17.91 | 10 ± 4.49 | - |
| Ortigoza (2022) | 468 | 473 | 59% | 62.65 ± 15.59 | 6.65 ± 3.71 | 250 |
| Ray (2022) | 40 | 40 | 71% | - | 4.20 ± 2.21 | 400 |
| Rojas (2022) | 46 | 45 | 70% | 51.76 ± 18.68 | 10.65 ± 2.96 | 500 |
| Santis (2022) | 36 | 71 | 72% | 56.00 ± 16.16 | 9.00 ± 1.50 | 1800 |
| Sekine (2022) | 80 | 80 | 41% | 58.74 ± 14.96 | 10.00 ± 3.00 | 300 |
| Self (2022) | 487 | 473 | 57% | 59.65 ± 15.59 | 7.65 ± 3.72 | 300 |
| Simonovich (2021) | 228 | 105 | 67% | 62.00 ± 14.89 | 7.65 ± 3.72 | 500 |
| Sullivan (2022) | 592 | 589 | 57% | 43.35 ± 23.12 | 5.65 ± 2.23 | 250 |
| Thorlacius-Ussing (2022) | 98 | 46 | 72% | 65.00 ± 14.98 | 10.65 ± 3.76 | 600 |
| van de Berg (2022) | 52 | 51 | 41% | 77.20 ± 8.60 | 8.65 ± 3.76 | 250 |
Missing values were not reported either in the article or in the supplementary material. CP dose is the total convalescent plasma transfused.